Bariatric Surgery Candidate Clinical Trial
Official title:
Pharmacokinetics and Pharmacodynamics of Edoxaban in Subjects With Severe Obesity Before and After Sleeve Gastrectomy and Roux-en-Y Gastric Bypass
The study will be conducted at a single site in the Canada, Quebec. Participants will be recruited from the bariatric surgery clinic and will be required to be either, waiting for sleeve gastrectomy surgery (n=12, restrictive bariatric surgery, Group 1) or Roux-en-Y gastric bypass (n=12, mixed bariatric surgery, Group 1), or had underwent Roux-en-Y gastric bypass 12 ± 3 months ago (n=12, Group 2). Participants in Group 1, edoxaban pharmacokinetic and pharmacodynamics will be evaluated before and 48 ± 5 hours after bariatric surgery (sleeve gastrectomy and Roux-en-Y gastric bypass). Participants in Group 2, edoxaban pharmacokinetic and pharmacodynamics will be evaluated only once, at 12 ± 3 months following their Roux-en-Y gastric bypass. All participants will be received single oral doses of 60 mg edoxaban at each pharmacokinetic and pharmacodynamics evaluation.
Screening visit (Group 1 and 2: visit 1) // Group 1: Screening will take place within 3 to 4-months window before bariatric surgery. Group 2: Screening will take place within 1-months window approximately 12± 3 months after bariatric surgery. Informed consent will be obtained from the subject prior to performing any of the screening assessments. The following activities and/or assessments will be performed at/during Screening: Informed consent, Inclusion/exclusion criteria, Medical history, Concomitant medications, Physical examination, including height, weight, and body mass index (BMI), Blood and urine samples, 12-lead ECG, Vital signs. Pharmacokinetic (PK) and pharmacodynamics (PD) visit Group 1: PK and PD visit will take place after the screening visit and within 3-months window before bariatric surgery as well as 48 hours after bariatric surgery. Group 2: PK and PD visit will take place after the screening visit and within 1-months window after bariatric surgery (12± 3 months). On PK and PD visit, the following procedures will be performed: Vital signs, ECG, Concomitant medications, Edoxaban dosing (before 8:00 AM), Pharmacokinetics (PK) and Pharmacodynamics (PD) blood draws (predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours), Post dose fasting and water restrictions, as appropriate, Adverse event (AE) monitoring. Follow-up 1 - Group 1 and Group 2: Follow-up 1 will take place onsite 24 hours after PK and PD visits. On follow-up 1, the following procedures will be performed: PK and PD blood draws, Concomitant medications, AE monitoring. Follow-up 2 - Group 1 and Group 2: Follow-up 2 will be a phone contact and will take place 7 days after PK and PD visits. On follow-up 2, the following procedures will be performed: Concomitant medications, AE monitoring. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Active, not recruiting |
NCT04583683 -
Effects of Very Low Calorie Diet vs Metabolic Surgery on Weight Loss and Obesity Comorbidities
|
N/A | |
Completed |
NCT04099654 -
The Effect of Core Stabilization Exercise Program in Obese Subjects Awaiting Bariatric Surgery
|
N/A | |
Completed |
NCT03809182 -
Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels.
|
Phase 4 | |
Completed |
NCT03638843 -
Endoscopic Gastric Mucosal Devitalization (GMD) as a Primary Obesity Therapy - Part 2
|
N/A | |
Withdrawn |
NCT05845359 -
Intraoperative Methadone for Postoperative Pain Control
|
Phase 4 | |
Not yet recruiting |
NCT04343040 -
Perioperative Evaluation of Glucose Profile Using Continuous Glucose Monitoring System in Glucose Intolerant Patients
|
N/A | |
Withdrawn |
NCT03095404 -
Intravenous Lidocaine for Post-Operative Pain Control in Patients Undergoing Bariatric Bowel Surgery
|
Early Phase 1 | |
Recruiting |
NCT03100292 -
Korean OBEsity Surgical Treatment Study
|
N/A | |
Active, not recruiting |
NCT04357119 -
Common Limb Length in One-anastomosis Gastric Bypass
|
N/A | |
Completed |
NCT03210207 -
Gastric Plication in Mexican Patients
|
N/A | |
Completed |
NCT04883268 -
Focusing on Body Functionality After Bariatric Surgery
|
N/A | |
Completed |
NCT02300168 -
Neuromuscular Blockade: Outcome and Recovery for Laparoscopic Bariatric Surgery
|
N/A | |
Unknown status |
NCT01264120 -
The Impact of a Bariatric Rehabilitation Service on Patient Outcomes
|
N/A | |
Recruiting |
NCT03972319 -
Omega-3 Supplementation for LIver VolumE Reduction Study (OLIVER) Study
|
Early Phase 1 | |
Terminated |
NCT04626232 -
Comparison of the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique in Morbidly Obese Patients
|
N/A | |
Completed |
NCT03643783 -
Impact of Plasma Soluble Prorenin Receptor in Obese and Type 2 Diabetic Patients
|
||
Completed |
NCT04219852 -
Contraception and Bariatric Surgery: Evaluation of Contraception and Contraceptive Knowledge of Women Undergoing Bariatric Surgery at the University Hospital of Reims
|
||
Recruiting |
NCT05570474 -
Effect of Protein Supplementation on Fat Free Mass Preservation After Bariatric Surgery
|
N/A |